Opko Ireland Global Holdings, Limited

Cytochroma Inc.

Opko Renal, LLC

Eirgen Pharma Ltd.

Queen's University at Kingston

Johns Hopkins University

Proventiv Therapeutics, LLC

Other

Opko IP Holdings Ii, Inc.

Jay A White

Samir P Tabash

P Martin Petkovich

Charles W Bishop

Sammy Asiamah Agudoawu

Glenville Jones

Joel Z Melnick

Eric J Messner

Keith H Crawford

Barbara R Beckett

Stephen A Strugnell

Susan Peers

Gary H Posner

Martin Petkovich

Heather Ramshaw

Byung-Chul Suh

Hong Woon Yang

Kenneth R Crawford

Heung Bae Jeon

Qiang Wang

Mehmet Kahraman

Uttam Saha

Susan H Peers

Steven M Silverman

HeungBae Jeon

Mark Hatcher

Bethany Halford

Sammy A Agudoawu

Jae Kyoo Lee

A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation can comprise one or both of 25-hydroxyvitamin Dand 25-hydroxyvitamin Dand a stabilizing compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

Stabilized modified release vitamin D formulation and method of administering same

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

Adjunctive therapy with 25-hydroxyvitamin D and articles therefor

Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxy vitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxy vitamin D.

Methods and compositions for reducing parathyroid levels

A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin Dand 25-hydroxyvitamin Dand a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

Stabilized modified release Vitamin D formulation and method of administering same

A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.

Methods for controlled release oral dosage of a vitamin D compound

Method for treating secondary hyperparathyroidism in CKD

Method for controlled release oral dosage of a vitamin D compound

Growing community of inventors

Newmarket, Canada

Jay A White